PATENT CLAIM ANALYSIS

Application Number: 15874430
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-05
Patent Classification: ["514", "006900"]

Abstract:
The present invention is directed to a method of treating a metabolic disorder or key elements of a metabolic disorder such method comprising the use of an agent(s) that increases central dopaminergic activity plus a first-phase insulin secretagouge.

Claim (Index 13):
A pharmaceutical dosage form of 1) a short acting agent that increases central dopaminergic activity at a specific time of day and of 2) a long acting FPIS that increases postprandial insulin at meals across the day for once daily administration to a subject with a metabolic disorder in need of treatment of such metabolic disorder.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 86.0
- Lexical Diversity: 1.23529
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15165485', '14506353', '13375810', '12154907', '14048880']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7796473660457155
- 35 USC 102 Novelty (BERT): 0.6053178881582765
- Combined Prediction Score: 0.7622144182569717
- Mean Citation Score: 473.91606
- Max Citation Score: 599.9459
- Similarity Product: 430.3099388966382

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test